| Website | ignyta.com |
| @Ignyta | |
| Category | BioTech |
| info@ignyta.com | |
| Employees | |
| Founded | 2011 |
| Actagene Oncology, 5/13 |
| TOTAL | $5.5M |
| FUNDING TOTAL | $5.5M |
| Series B, 12/12 City Hill Ventures Colt Ventures | $5.5M |
| DEBT TOTAL | $1M |
| Debt, 2/13 | $1M |
Ignyta is a scientifically driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goals are to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
